Translational PET imaging research

Neurobiology of Disease

Volumn 61, Issue , 2014, Pages 32-38

  Hargreaves, Richard J ^a   Rabiner, Eugenii A ^b,c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Drug development; Positron emission tomography (PET) imaging; Psychiatry imaging; Target engagement imaging

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA5; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; APREPITANT; CARBON; CARBON 11; FLUORODEOXYGLUCOSE F 18; KETAMINE; L 759274; LORAZEPAM; MRK 409; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; NITROGEN; NITROGEN 13; OXYGEN 15; PHENCYCLIDINE; PLACEBO; RACLOPRIDE C 11; TPA 023; TPA 123; UNCLASSIFIED DRUG;

ANXIETY DISORDER; CENTRAL NERVOUS SYSTEM; DEPRESSION; DOSIMETRY; DRUG ANTAGONISM; DRUG BINDING; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG LABELING; DRUG MANUFACTURE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; ISOTOPE LABELING; MAJOR DEPRESSION; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TRANSLATIONAL RESEARCH;

DRUG DEVELOPMENT; POSITRON EMISSION TOMOGRAPHY (PET) IMAGING; PSYCHIATRY IMAGING; TARGET ENGAGEMENT IMAGING;

CENTRAL NERVOUS SYSTEM AGENTS; DRUG DISCOVERY; HUMANS; MENTAL DISORDERS; POSITRON-EMISSION TOMOGRAPHY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84888069982     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.08.017     Document Type: Review

References (86)

1. Abanades S., van der Aart J., Barletta J.A.R., Marzano C., Searle G.E., Salinas C.A., et al. Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy. J. Cereb. Blood Flow Metab. 2011, 31:944-952.
2. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Siebyl J., Bowers M., et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry 1998, 155:761-767.
3. 2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:8104-8109.
4. Addy C., Wright D.H., Van Laere K., Gantz I., Erondu N.E., Musser B.J., et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab. 2008, 7:68-78.
5. 1B receptor: radiosynthesis and characterization in cynomolgus monkeys of eight radiolabeled compounds. Nucl. Med. Biol. 2011, 38:261-272.
6. 3 receptor in humans using PET. J. Nucl. Med. 2010, 51:1021-1029.
7. Atack J.R., Wafford K.A., Street L.J., Dawson G.R., Tye S.J., Agrawal N.G.B., et al. MRK-409, a gaba alpha receptor subtype-selective agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in man. J. Psychopharmacol. 2010, 25:314-328.
8. A/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes. J. Pharmacol. Exp. Ther. 2010, 332:4-16.
9. Bacher I., Houle S., Xu X., Zawertailo L., Soliman A., Wilson A.A., et al. Monoamine oxidase A binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking. Arch. Gen. Psychiatry 2011, 68:817-826.
10. 11C]MK-4232: the first positron emission tracer for the calcitonin gene-related peptide receptor. ACS Med. Chem. Lett 2013, 4(9):863-868.
11. 11C-raclopride. Psychopharmacology 1993, 112:308-314.
12. 11C] labelled selective high affinity NK1-antagonists, GR203040 and GR205171 - PET studies in rhesus monkey. Neuropharmacology 2000, 39:664-670.
13. Bergstrom M., Grahnen A., Langstrom B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur. J. Clin. Pharmacol. 2003, 59:357-366.
14. Bergstrom M., Hargreaves R.J., Burns H.D., Goldberg M.R., Sciberras D., Reines S.A. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol. Psychiatry 2004, 55:1007-1012.
15. Bergstrom M., Yates R., Wall A., Kagedal M., Syvanen S., Langstrom B. Blood-brain barrier penetration of zolmitriptan-modelling of positron emission tomography data. J. Pharmacokinet. Pharmacodyn. 2006, 33:75-91.
16. 11C]WAY-100635. Mol. Psychiatry 2004, 9:386-392.
17. 11C]MDL 100,907. Am. J. Psychiatry 2006, 163:1580-1587.
18. Borsook D., Becerra L., Hargreaves R.J. A role for fMRI in CNS drug development. Nat. Rev. Drug Discov. 2006, 5:411-424.
19. Borsook D., Becerra L., Bullmore E., Hargreaves R. The challenges and the opportunities. Imaging in CNS Drug Discovery and Development 2009, 3-9. Springer, New York. D. Borsook, L. Becerra, E. Bullmore, R. Hargreaves (Eds.).
20. Borsook D., Becerra L., Bullmore E., Hargreaves R. Reasons to believe: Potential of imaging in CNS drug development. Imaging in CNS Drug Discovery and Development 2009, 381-386. Springer, New York. D. Borsook, L. Becerra, E. Bullmore, R. Hargreaves (Eds.).
21. 18F] MK-9470 a positron emission tomography tracer (PET) for in vivo human PET brain imaging of the cannabinioid-1 receptor. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:9800-9805.
22. Ding Y.-S., Lin K.-S., Garza V., Carter P., Alexoff D., Logan J., et al. Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs. Synapse 2003, 50:345-352.
23. 18F]fluororeboxetine), (R)-[11C]nisoxetine, [11C]oxaprotiline and [11C]lortalamine. J. Neurochem. 2005, 94:337-351.
24. Drevets W.C., Frank E., Price J.C., Kupfer D.J., Holt D., Greer P.J., et al. PET imaging of serotonin 1A receptor binding in depression. Biol. Psychiatry 1999, 46:1375-1387.
25. 11C] flumazenil PET imaging. Neuropharmacology 2010, 59:635-639.
26. Erondu N., Gantz I., Musser B., Suryawanshi S., Mallick M., Addy C., et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 2006, 4:275-282.
27. Farde L., Wiesel F.A., Halldin C., Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry 1988, 45:71-76.
28. Farde L., Mack R.J., Nyberg S., Halldin C. D2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy subjects. Int. Clin. Psychopharmacol. 1997, 12(Suppl. 1):S3-S8.
29. 1B-receptors in the primate brain. Synapse 2010, 64:573-577.
30. Frank R., Hargreaves R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2003, 2:566-580.
31. 11C]P943 in humans. J. Cereb. Blood Flow Metab. 2010, 30:196-210.
32. 2 receptors in the rhesus monkey brain in vivo. Synapse 2012, 66:489-500.
33. Grunder G.G., Hippius H., Carlsson A. The atypicality of antipsychotics-a concept re-examined and re-defined. Nat. Rev. Drug Discov. 2009, 8:197-202.
34. Gunn R.N., Salinas C.A., Read K.R., Searle G., Ruffo A.D., Parker C.A., et al. Combining PET and equilibrium dialysis to assess blood-brain-barrier transport. J. Cereb. Blood Flow Metab. 2007, 27:4-14.
35. Gunn R.N., Summerfield S.G., Salinas C.A., Read K.R., Guo Q., Searle G.E., et al. Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs. J. Cereb. Blood Flow Metab. 2012, 32:874-883.
36. 11C]β-CIT-FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography. Synapse 1996, 22:386-390.
37. 5) PET radiotracers. Synapse 2005, 56:205-216.
38. Hamill T., Sato N., Jitsuoka M., Tokita S., Sanabria S., Eng W., et al. Inverse agonist histamine H3 receptor PET tracers labelled with carbon-11 or fluorine-18. Synapse 2009, 63:1122-1132.
39. 11C]CMPyPB, glycine transporter 1 (GlyT1) PET radiotracers. Synapse 2011, 65:261-270.
40. Hargreaves R.J. Imaging substance P (neurokinin 1) receptors in the living human brain using positron emission tomography. J. Clin. Psychiatry 2002, 63(Suppl. 1):18-24.
41. Hargreaves R.J. The role of molecular imaging in drug discovery and development. Clin. Pharmacol. Ther. 2007, 83:349-353.
42. Hargreaves R., Grachev I. Integrative processes. Neuroscience clinical imaging biomarkers. Imaging in CNS Drug Discovery and Development 2009, 363-379. Springer, New York. D. Borsook, L. Becerra, E. Bullmore, R. Hargreaves (Eds.).
43. Hargreaves R., Wagner J.A. Imaging as a biomarker for decision making in drug development. In Vivo MR Techniques in Drug Discovery and Development 2006, 31-44. Taylor & Francis, New York. N. Beckmann (Ed.).
44. Hargreaves R.J., Borsook D., Becerra L. Can functional magnetic resonance imaging improve success rates in central nervous system drug discovery?. Expert Opin. Drug Discov. 2011, 6:597-617.
45. Hargreaves R.J., Becerra L., Borsook D. Biomedical Imaging: The Chemistry of Labels, Probes and Contrast Agents 2012, 411-440. The Royal Society of Chemistry, Cambridge, UK. M. Braddock (Ed.).
46. 1 receptor occupancy by MK-5435. Synapse 2010, 65:125-135.
47. 18F]Y1-973, a PET tracer for the neuropeptide Y Y1 (NPY-Y1) receptor. NeuroImage 2011, 54:2635-2642.
48. Hostetler E., Joshi A.D., Sanabria-Bohorquez S., Fan H., Zeng Z., Purcell M., et al. In vivo quantification of calcitonin gene related peptide (CGRP) receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography (PET) tracer [11C] MK4232. J. Pharmacol. Exp. Ther. 2013, 347:1-9. 10.1124/jpet.113.206458.
49. Howes O.D., Egerton A., Allan V., McGuire P., Stokes P., Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr. Pharm. Des. 2009, 15:2550-2559.
50. Howes O.D., Montgomery A.J., Asselin M.C., Murray R.M., Valli I., Tabraham P., et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 2009, 66:13-20.
51. Howes O.D., Fusar-Poli P., Bloomfield M., Selvaraj S., McGuire P. From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments. Curr. Pharm. Des. 2012, 18:459-465.
52. Jones T., Rabiner E.A. The development, past achievements, and future directions of brain PET. J. Cereb. Blood Flow Metab. 2012, 32:1426-1454.
53. Kalbitzer J., Erritzoe D., Holst K.K., Nielsen F.A., Marner L., Lehel S., et al. Seasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotes. Biol. Psychiatry 2010, 67:1033-1039.
54. 1A receptors in patients with major depressive disorder. Research letter. Psychol. Med. 2010, 40:523-528.
55. Keller M., Montgomery S., Ball W.A., Morrison M.F., Snavely D.B., Liu G.F., et al. Lack of efficacy of the substance P (neurokinin 1 receptor) antagonist aprepitant in the treatment of major depressive disorder: results from 5 placebo controlled clinical trials and a PET study. Biol. Psychiatry 2006, 59:216-223.
56. Kiesewetter D.O., Jagoda E.M., Starrett J.E., Gribkoff V.K., Hewawasam P., Srinivas N., et al. Radiochemical synthesis and biodistribution of a novel maxi-K potassium channel opener. Nucl. Med. Biol. 2002, 29:55-59.
57. 11C]PBR28, two radioligands for translocator protein (18kDa) in human and monkey: implications for positron emission tomographic imaging of this inflammation biomarker. NeuroImage 2010, 49:2924-2932.
58. Liu P., Hamill T.G., Chioda M., Chobanian H., Fung S., Guo, et al. Discovery of MK-3168: a PET tracer for imaging fatty acid amino hydrolase. ACS Med. Chem. Lett. 2013, 4:509-513.
59. 2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am. J. Psychiatry 2004, 161:818-825.
60. 4 receptors in the human brain in vivo. J. Nucl. Med. 2009, 50:900-908.
61. 18F-FECNT: validation as PET dopamine transporter ligand in Parkinsonism. Exp. Neurol. 2010, 226:265-273.
62. Matthews P.M., Rabiner E.A., Passchier J., Gunn R.N. Positron emission tomography molecular imaging for drug development. Br. J. Clin. Pharmacol. 2012, 73:175-186.
63. Meyer J.H. Applying neuroimaging ligands to study major depressive disorder. Semin. Nucl. Med. 2008, 38:287-304.
64. 2 receptors during depression and self-harm. Am. J. Psychiatry 2003, 160:90-99.
65. 11C] DASB positron emission tomography study. Am. J. Psychiatry 2004, 161:826-835.
66. Meyer J.H., Wilson A.A., Sagrati S., Miler L., Rusjan P., Bloomfield P.M., et al. Brain monoamine oxidase A binding in major depressive disorder. Relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch. Gen. Psychiatry 2009, 66:1304-1312.
67. Michelson D., Hargreaves R.J., Alexander R.C., Ceesay T.P., Hietala J., Lines C.R., et al. Lack of efficacy of L-759274, a novel neurokinin1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder. Int. J. Neuropsychopharmacol. 2013, 16:1-11.
68. Miller P.W., Long N.J., Vilar R., Gee A.D. Synthesis of 11C, 18F, 15O and 13N radiolabels for positron emission tomography. Angew. Chem. Int. Ed. 2008, 47:8998-9033.
69. 11C]GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography. Synapse 2010, 64:542-549.
70. Patterson L.M., Kornum B.R., Nutt D.J., Pike V.W., Knudsen G.M. 5-HT radioligands for human brain imaging with PET and SPECT. Med. Res. Rev. 2013, 33:54-111.
71. Praschak-Rieder N., Willeit M., Wilson A.A., Houle S., Meyer J.H. Seasonal variation in human brain serotonin transporter binding. Arch. Gen. Psychiatry 2008, 65:1072-1078.
72. Rabiner E.A., Slifstein M., Nobrega J., Plisson C., Huiban M., Raymond R., et al. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice. Synapse 2009, 63:782-793.
73. Rabiner E.A., Beaver J., Makwana A., Searle G., Long C., Nathan P.J., et al. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. Mol. Psychiatry 2011, 16:826-835.
74. 11C] P943: a positron emission tomography study in Papio anubis. Synapse 2011, 65:1119-1127.
75. 123I]β-CIT SPECT in major depressive disorder versus controls: effect of season and gender. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:841-849.
76. Sacher J., Wilson A.A., Houle S., Rusjan P., Hassan S., Bloomfield P.M., et al. Elevated brain monoamine oxidase A binding in the early postpartum period. Arch. Gen. Psychiatry 2010, 67:468-474.
77. 11C]WAY-100635. Effects of depression and antidepressant treatment. Arch. Gen. Psychiatry 2000, 57:174-180.
78. 3 receptor antagonist. Biol. Psychiatry 2010, 6:392-399.
79. 11C] raclopride sensitivity to acute amphetamine challenge in healthy humans. J. Cereb. Blood Flow Metab. 2012, 32:127-136.
80. 18F]SPA-RQ). Mol. Imaging Biol. 2004, 6:373-384.
81. 18F]SPA-RQ: comparison of thin-slice, bisected, and 2-dimensional planar image analysis. J. Nucl. Med. 2007, 48:100-107.
82. Terry G.E., Hirvonen J., Liow J.S., Zoghbi S.S., Gladding R., Tauscher J.T., et al. Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using 18F-labeled inverse agonist radioligands. J. Nucl. Med. 2010, 51:112-120.
83. Varrone A., Halldin C. Molecular imaging of the dopamine transporter. J. Nucl. Med. 2010, 51:1331-1334.
84. 2 high-affinity state with positron emission tomography. J. Med. Chem. 2005, 48:4153-4160.
85. 11C]CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography. Nucl. Med. Biol. 2011, 38:247-253.
86. Zamuner S., Gomeni R., Bye A. Estimate the time varying brain receptor occupancy in PET imaging experiments using non-linear fixed and mixed effect modeling approach. Nucl. Med. Biol. 2002, 29:115-123.